Stockreport

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, a [Read more]